atazanavir sulfate has been researched along with cobicistat in 24 studies
Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (cobicistat) | Trials (cobicistat) | Recent Studies (post-2010) (cobicistat) |
---|---|---|---|---|---|
1,102 | 246 | 590 | 300 | 75 | 282 |
Protein | Taxonomy | atazanavir sulfate (IC50) | cobicistat (IC50) |
---|---|---|---|
Cytochrome P450 3A4 | Homo sapiens (human) | 0.15 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 9.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 21 (87.50) | 24.3611 |
2020's | 3 (12.50) | 2.80 |
Authors | Studies |
---|---|
Chuck, SL; Cohen, C; Elion, R; Gathe, J; Hawkins, T; Kearney, BP; Liu, HC; Mathias, AA; Shalit, P; Warren, DR | 1 |
Cheng, AK; DeJesus, E; Gathe, J; Henry, K; Kearney, BP; Molina, JM; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X; White, K; Yale, K | 1 |
Pommer, P | 1 |
Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X | 1 |
Cahn, P; Sued, O | 1 |
Andrade-Villanueva, J; Antunes, F; Arastéh, K; Callebaut, C; Cheng, AK; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, Y; Moyle, G; Rhee, MS; Rizzardini, G; Szwarcberg, J; Zhong, L | 1 |
Deeks, ED | 1 |
Bertz, R; Jariwala, N; Ravindran, P; Sevinsky, H; Sims, K; Tao, X; Wang, R; Xu, X | 1 |
Abram, ME; Andrade-Villanueva, JF; Antunes, F; Arastéh, K; Cao, H; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, HC; Rizzardini, G; Szwarcberg, J | 1 |
Ferguson, K; Klibanov, OM; Phan, D | 1 |
Back, D; Gibbons, S; Khoo, S; Marzolini, C | 1 |
Jones, R; Levy, JB; Milburn, J | 1 |
Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Johnson, M; Kityo, C; Koenig, E; Squires, K; Szwarcberg, J; Voronin, E; White, K | 1 |
Berenguer, J; Cao, H; Gallant, J; Liu, YP; Moyle, G; Myers, J; Rosenblatt, L; Shalit, P; Szwarcberg, J; Yang, L | 1 |
Burger, DM; Colbers, EP; de Kanter, CT; Drenth, JP; Smolders, EJ; Velthoven-Graafland, K | 1 |
Luetkehoelter, J; Tseng, AL; Walmsley, SL | 1 |
Amara, A; Boffito, M; Elliot, ER; Else, L; Higgs, C; Khoo, S; Moyle, G; Pagani, N; Schoolmeesters, A | 1 |
Antunes, F | 1 |
Hughes, CA; Phillips, EJ; Seet, J; Tseng, A; Wu, J | 1 |
Cattaneo, D; Formenti, T; Fossati, A; Gervasoni, C; Meraviglia, P; Minisci, D; Resnati, C | 1 |
Das, M; Kearney, BP; Ling, KH; Majeed, SR; West, S | 1 |
Badell, ML; Best, BM; Browning, R; Capparelli, EV; Chakhtoura, N; Denson, K; George, K; Mirochnick, M; Momper, JD; Paul, ME; Powis, KM; Rungruengthanakit, K; Shapiro, DE; Stek, A; Wang, J | 1 |
Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R | 1 |
Abbot, V; Kapila, I; Sharma, A; Sharma, P | 1 |
5 review(s) available for atazanavir sulfate and cobicistat
Article | Year |
---|---|
Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
Topics: Atazanavir Sulfate; Carbamates; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Synergism; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Sulfonamides; Thiazoles | 2014 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
Atazanavir sulfate + cobicistat for the treatment of HIV infection.
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Cobicistat; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Patient Safety; Solubility; Treatment Outcome | 2017 |
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; Quinolones; Ritonavir | 2017 |
A Combination of Novel HIV-1 Protease Inhibitor and Cytochrome P450 (CYP) Enzyme Inhibitor to Explore the Future Prospective of Antiviral Agents: Evotaz.
Topics: Anti-HIV Agents; Anti-Infective Agents; Antiviral Agents; Atazanavir Sulfate; Child; Cobicistat; Cytochrome P-450 Enzyme System; Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Protease Inhibitors; United States | 2023 |
11 trial(s) available for atazanavir sulfate and cobicistat
Article | Year |
---|---|
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; Tenofovir; Thiazoles | 2012 |
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides | 2013 |
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2013 |
A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents.
Topics: Administration, Oral; Adolescent; Adult; Atazanavir Sulfate; Biological Availability; Cobicistat; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Healthy Volunteers; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Therapeutic Equivalency; Young Adult | 2015 |
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Viral Load | 2015 |
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cobicistat; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; International Cooperation; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2016 |
Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; RNA, Viral; Sustained Virologic Response; Treatment Outcome; Withholding Treatment | 2017 |
Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Female; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ritonavir; Valine; Young Adult | 2017 |
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Female; Half-Life; Healthy Volunteers; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Saliva; Young Adult | 2017 |
Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
Topics: Adolescent; Adult; Androstenes; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Cobicistat; Cohort Studies; Contraceptives, Oral, Hormonal; Darunavir; Drug Interactions; Ethinyl Estradiol; Female; Half-Life; Humans; Mineralocorticoid Receptor Antagonists; Young Adult | 2019 |
8 other study(ies) available for atazanavir sulfate and cobicistat
Article | Year |
---|---|
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2012 |
Boosting HIV treatment options: good news, new challenges.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles | 2013 |
Drug updates and approvals: 2015 in review.
Topics: Amlodipine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atazanavir Sulfate; Azabicyclo Compounds; Benzazepines; Ceftazidime; Cobicistat; Drug Approval; Drug Combinations; Humans; Injections, Subcutaneous; Ivabradine; Liraglutide; Nurse Practitioners; Perindopril; Pyridines; Thiazoles; United States; United States Food and Drug Administration | 2015 |
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir | 2016 |
Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal.
Topics: Aged; Anti-HIV Agents; Anticoagulants; Atazanavir Sulfate; Blood Chemical Analysis; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; International Normalized Ratio; Male; Ritonavir; Warfarin | 2017 |
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2018 |
Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Child; Cobicistat; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Placenta; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies | 2022 |
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States | 2022 |